methyl 2-[[(benzyloxy)carbonyl]amino]-3-[(tert-butyloxycarbonyl)amino]propanoate | 315498-37-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl 2-[[(benzyloxy)carbonyl]amino]-3-[(tert-butyloxycarbonyl)amino]propanoate
• 英文别名: methyl 2-[[(benzyloxy)carbonyl]amino]-3-[(tert-butoxycarbonyl)amino]propanoate；methyl 3-(tert-butyloxycarbonylamino)-2-(benzyloxycarbonylamino)propionate；methyl 3-[(2-methylpropan-2-yl)oxycarbonylamino]-2-(phenylmethoxycarbonylamino)propanoate
• CAS: 315498-37-4
• 化学式: C₁₇H₂₄N₂O₆
• 分子量: 352.387
• InChiKey: MDMZRMHNXPKKND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  25
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  methyl 2-[[(benzyloxy)carbonyl]amino]-3-[(tert-butyloxycarbonyl)amino]propanoate 、 三氟乙酸 以 甲苯 为溶剂， 反应 1.0h， 生成 methyl ester of N-alpha-(CO2-CH2-phenyl)-alpha,beta-diaminopropionic acid
  参考文献：
  名称：

  ACYLHYDRAZINE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND USE THEREOF

  摘要：

  公开号：

  EP1188755B1
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 Z-DL-天冬酰胺酸 、 [双(三氟乙酰氧基)碘]苯 在 potassium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 13.0h， 生成 methyl 2-[[(benzyloxy)carbonyl]amino]-3-[(tert-butyloxycarbonyl)amino]propanoate
  参考文献：
  名称：

  ACYLHYDRAZINE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND USE THEREOF

  摘要：

  公开号：

  EP1188755B1

文献信息

• Acylhydrazine derivatives, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06723722B1

  公开（公告）日：2004-04-20

  Novel acylhydrazine derivatives exhibiting an inhibitory activity against activated blood coagulation factor X, which are compounds of general formula (I) or salts thereof, wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; R1 and R2 are each hydrogen or optionally substituted hydrocarbyl, or alternatively R1 and R2 or the substituent of X1 and R2 may be united to form an optionally substituted ring; X1 and X2 are each free valency, optionally substituted alkylene, or optionally substituted imino; D is oxygen or sulfur; A is —N(R3)—Y— or —N═Y—, R3 is hydrogen, optionally substituted hydrocarbyl, or acyl; Y is an optionally substituted chain hydrocarbon group or an optionally substituted cyclic group; and Z is (1) optionally substituted amino, (2) optionally substituted imidoyl, or (3) an optionally substituted nitrogenous heterocycle group.

  具有抑制活化血凝因子X抑制活性的新型酰肼衍生物，其为一般式(I)或其盐的化合物，其中R为可选取代的碳氢基团或可选取代的杂环基团；R1和R2分别为氢或可选取代的碳氢基团，或者R1和R2或X1的取代基和R2可以结合形成可选取代的环；X1和X2分别为自由价、可选取代的烷基或可选取代的亚胺基；D为氧或硫；A为-N(R3)-Y-或-N═Y-，其中R3为氢、可选取代的碳氢基团或酰基；Y为可选取代的链烃基团或可选取代的环状基团；Z为(1)可选取代的氨基、(2)可选取代的亚氨基或(3)可选取代的含氮杂环基团。
• PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS
  申请人：Corte James R.

  公开号：US20110021492A1

  公开（公告）日：2011-01-27

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein the variables A, L 1 , L 2 , R 2 , R 11 , and M are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供公式（I）的化合物：或其立体异构体，互变异构体或药学上可接受的盐，其中变量A，L1，L2，R2，R11和M如本文所定义。这些化合物是选择性因子XIa抑制剂或fXIa和血浆卡利肽酶双重抑制剂。本发明还涉及包含这些化合物的制药组合物和使用它们治疗血栓栓塞和/或炎症性疾病的方法。
• Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10221167B2

  公开（公告）日：2019-03-05

  Disclosed are compounds of Formula A, or a salt thereof: wherein R1, R2, and E are defined herein, which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain disorders, cough, and itch using the same.

  公开了式 A 的化合物或其盐： 其中 R1、R2 和 E 在此定义，这些化合物具有抑制外周神经元和交感神经元中 Nav 1.7 离子通道的特性。还描述了包含式 A 化合物或其盐类的药物制剂，以及用其治疗疼痛疾病、咳嗽和瘙痒的方法。
• Metallo-beta-lactamase inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10221163B2

  公开（公告）日：2019-03-05

  The present invention relates to metallo-beta-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-beta-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta-lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.

  本发明涉及式 I 的金属-β-内酰胺酶抑制剂化合物：及其药学上可接受的盐，其中 Z、RA、X1、X2 和 R1 如本文所定义。本发明还涉及组合物，其包含本发明的金属-β-内酰胺酶抑制剂化合物或其药学上可接受的盐，以及药学上可接受的载体，可选择与β-内酰胺抗生素和/或β-内酰胺酶抑制剂结合使用。本发明进一步涉及治疗细菌感染的方法，包括向患者施用治疗有效量的本发明化合物，与治疗有效量的一种或多种β-内酰胺类抗生素联合使用，也可选择与一种或多种β-内酰胺酶抑制剂化合物联合使用。本发明的化合物在本文所述的克服抗生素耐药性的方法中是有用的。
• 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3313832B1

  公开（公告）日：2021-02-24